First-in-Class Menin Inhibitor Disrupts Oncogenic KMT2A Protein Complex Transcription
The FDA announced on November 15, 2026, approval of Revuforj (revumenib) tablets, developed by Syndax Pharmaceuticals, Inc., as a first-in-class oral menin inhibitor indicated for adult and pediatric patients aged one year and older with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A (KMT2A) translocation. According to FDA Center for Drug Evaluation and Research (CDER) review documentation, KMT2A translocations are present in approximately 10% to 15% of pediatric acute leukemias and roughly 5% to 10% of adult acute leukemias, spanning acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Revuforj binds into the interaction pocket shared between menin and oncogenic KMT2A fusion proteins, disrupting transcriptional activating complexes and suppressing HOXA9 and MEIS1.
In the single-arm, open-label AUGMENT-101 trial, revumenib achieved a complete remission with partial hematologic recovery (CR/CRh) rate of 21.2%, with a median remission duration of 6.4 months; nearly 40% of responding patients transitioned to allogeneic hematopoietic stem cell transplantation.
The FDA approved Revuforj with a Boxed Warning for differentiation syndrome and cardiac QTc interval prolongation. During pivotal clinical evaluation, differentiation syndrome occurred in 16% of treated patients, with Grade 3 manifestations in 2.9%; prescribing documentation instructs oncologists to initiate high-dose intravenous dexamethasone at earliest clinical suspicion and details mandatory baseline electrocardiogram and electrolyte monitoring and downward dose recalibrations with strong cytochrome P450 (CYP) 3A4 inhibitors.
Commercial leadership at Syndax confirmed Revuforj will be distributed through specialized national oncology pharmacy networks within weeks, and the company initiated administrative filings with public and private commercial health plans to establish formal specialty reimbursement tiers. International hematology researchers noted that menin inhibitors demonstrate preclinical activity across NPM1-mutated acute myeloid leukemias, approximately 30% of adult AML cases; ongoing research initiatives are evaluating revuforj in combination with BCL-2 inhibitors and hypomethylating agents.
